Inside Precision Medicine June 4, 2024
Researchers at University College London (UCL) and University College London Hospitals (UCLH) have discovered that an immunotherapy drug, pembrolizumab, significantly increases the number of patients who are cancer-free after surgery for bowel cancer, according to interim results from the NEOPRISM-CRC phase II clinical trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024.
The study investigated whether pembrolizumab could improve outcomes for patients with stage two or stage three MMR deficient/MSI-High bowel cancer. This genetic profile, present in 10–15 percent of stage two or three bowel cancer patients, represents about 2,000–3,000 cases annually in the U.K. The trial included 32 patients from five U.K. hospitals who were treated with pembrolizumab for nine weeks before surgery instead of...
Today's Sponsors
Today's Sponsor